Search

Sodium phosphate, dibasic

Pipendoxifene

ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

Sirolimus

[A242412] In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

Odevixibat

[A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]

Gilteritinib

[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

Gadobenic acid

[A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166]

Rilpivirine

[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021.

Oxilofrine

Oxilofrine is used in combination with DB11609 as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

Sodium borate

Coagulation factor X human

Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors